The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies.
 
Shannon Neville Westin
Consulting or Advisory Role - Amgen (I); Novartis (I); Spectrum Pharmaceuticals (I)
Research Funding - AstraZeneca; Biomarin; Celgene (I); GlaxoSmithKline; Janssen (I); Karyopharm Therapeutics (I); Merck; Millennium (I); Novartis; ProNAi (I); Spectrum Pharmaceuticals (I)
 
Erin Stashi
No Relationships to Disclose
 
Navdeep Pal
No Relationships to Disclose
 
Diana L Urbauer
No Relationships to Disclose
 
Filip Janku
Consulting or Advisory Role - Deciphera; Trovagene
Research Funding - Biocartis; BioMed Valley Discoveries; Foundation Medicine; Novartis; Roche; Trovagene
Other Relationship - Bio-Rad
 
Sarina Anne Piha-Paul
Research Funding - Abbvie; Bayer; Biomarin; Cerulean Pharma; Curis; Five Prime Therapeutics; GlaxoSmithKline; Helix BioPharma; Incyte; Merck; Novartis; Puma Biotechnology; Samumed; XuanZhu
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Apostolia Maria Tsimberidou
Honoraria - Medfusion
Research Funding - Baxter (Inst); Bayer (Inst); EMD Serono (Inst); Foundation Medicine (Inst); ONYX (Inst)
 
Siqing Fu
No Relationships to Disclose
 
David S. Hong
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
 
Vivek Subbiah
No Relationships to Disclose
 
Daniel D. Karp
No Relationships to Disclose
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; Gradalis; Merck; Merrimack; Millennium
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Razelle Kurzrock
Leadership - RScueRx Inc
Stock and Other Ownership Interests - Actuate Therapeutics; RScueRx
Honoraria - AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Cedars-Sinai; Frankel Group; Global Biomarkers Consortium; Janssen; Jubilant Biosys; NCCN; NXT Health Strategies; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; The Dedham Group; UCSD Genomics Program Talk
Consulting or Advisory Role - AACR; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom
Speakers' Bureau - Guardant Health
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; Foundation Medicine; Genentech Mypath; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; Merck; Merck; Novartis; Pfizer; Roche/Genentech; Sequenom; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; EMD Serono; EMD Serono & Quintiles; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Global Biomarkers Consortium; ICRP; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma